Ben Holland In the dynamic world of consumer health and wellness, Kenvue stands out as a powerhouse with a portfolio of iconic brands trusted by billions worldwide. But who owns Kenvue? As a publicly traded company, its ownership is distributed among institutional investors, with a significant stake still held by its parent company, Johnson & Johnson. However, a seismic shift is on the horizon: On November 3, 2025, Kimberly-Clark Corporation announced its intent to acquire Kenvue in a landmark $48.7 billion deal, potentially reshaping the landscape of global personal care and health products.
The Origins and History of Kenvue
Kenvue’s story is deeply intertwined with Johnson & Johnson (J&J), one of the world’s largest healthcare conglomerates. Founded in 1886, J&J built its consumer health division over decades, amassing beloved brands that became household staples. In November 2021, J&J unveiled plans to spin off this division to sharpen focus on its pharmaceutical and medical technology segments amid regulatory pressures and litigation challenges, including opioid-related lawsuits and talc powder controversies.
The spin-off materialized in 2023. Kenvue Inc. was incorporated on February 23, 2022, in Delaware, initially operating from Skillman, New Jersey, before moving its headquarters to Summit, New Jersey. The name “Kenvue” draws from “ken” (Scottish for knowledge) and “vue” (suggesting vision or perspective), symbolizing a fresh outlook on consumer care. The company went public via an initial public offering (IPO) on May 4, 2023, on the New York Stock Exchange under the ticker KVUE. Priced at $22 per share, the IPO raised $3.8 billion, marking the largest U.S. IPO since 2021 and valuing Kenvue at around $41 billion.
Post-IPO, J&J retained over 90% ownership. A share exchange offer in July 2023 allowed J&J shareholders to swap their stakes, completing the separation by August 2023. This left J&J with approximately 9.5% of Kenvue’s outstanding shares, solidifying Kenvue’s independence while maintaining a strategic minority position. Today, Kenvue employs about 22,000 people globally and touches the lives of over a billion consumers through its science-driven innovations in self-care.
This historical pivot wasn’t without hurdles. In March 2025, activist investor Starboard Value took a stake, prompting board changes and a strategic review. July 2025 saw the abrupt departure of CEO Thibaut Mongon, with Kirk Perry stepping in as interim CEO—a role he assumed permanently later that year. These events underscore the pressures of operating in a competitive market, including a 2023 securities class-action lawsuit over disclosures related to phenylephrine efficacy in certain products, which contributed to share price volatility.
Current Ownership Structure: A Public Company with Institutional Heavyweights
As of November 2025, Kenvue remains a publicly traded entity, with ownership dispersed among a diverse group of institutional investors. No single entity holds a controlling majority, reflecting the company’s status as an independent player in the consumer goods sector. Johnson & Johnson maintains its 9.5% stake, holding about 182.33 million shares, making it the largest individual shareholder.
Institutional ownership dominates, accounting for over 80% of shares. Leading the pack is The Vanguard Group, with approximately 8-9% (around 233 million shares as of September 2025), followed closely by T. Rowe Price Associates at 8.8% (168 million shares) and BlackRock Inc. at 7.7% (147.5 million shares). State Street Corporation rounds out the top tier with 6% (115 million shares). These investors, known for their long-term strategies in healthcare and consumer staples, provide stability amid market fluctuations.
Retail investors and other institutions fill the remainder, with recent filings showing activity from firms like GSA Capital Partners and Rothschild Investment LLC in November 2025. Kenvue’s corporate governance emphasizes board independence, with directors like activist Jeffrey Smith adding oversight. The 2025 Annual Meeting of Shareholders, held on May 22, highlighted commitments to ethical practices and shareholder value.
For those researching “Kenvue major shareholders 2025,” this structure signals resilience. High institutional interest underscores confidence in Kenvue’s brand equity, even as shares traded around $19.87 earlier in the year—below IPO levels—due to legal and operational headwinds.
The Game-Changing Kimberly-Clark Acquisition
The question of who owns Kenvue is evolving rapidly. On November 3, 2025, Kimberly-Clark, maker of Huggies and Kleenex, struck a deal to acquire Kenvue for an enterprise value of $48.7 billion—the largest consumer health merger in recent history. This cash-and-stock transaction values each Kenvue share at $21.01, comprising $3.50 in cash and 0.14625 Kimberly-Clark shares. Kenvue shareholders stand to receive $6.8 billion in upfront cash.
Post-closing, expected in the second half of 2026 pending regulatory and shareholder approvals, Kimberly-Clark shareholders will own 54% of the combined entity, while Kenvue shareholders hold 46%. The merger creates a $32 billion revenue behemoth with $7 billion in adjusted EBITDA, blending complementary portfolios: Kenvue’s health-focused brands with Kimberly-Clark’s hygiene essentials.
Strategic synergies are projected at $2.1 billion annually, including $1.9 billion in cost savings within three years and $500 million in revenue growth over four years, offset by $300 million in reinvestments for marketing and R&D. The deal is accretive to earnings per share by year two and enhances geographic reach, serving nearly half the world’s population across life stages. Despite a recent Tylenol recall controversy, the acquisition bets on Kenvue’s innovation pipeline to drive premiumization.
Kenvue’s Iconic Brand Portfolio
Ownership discussions often circle back to Kenvue’s assets. The company boasts over 20 powerhouse brands, generating $15.5 billion in 2024 revenue. Standouts include Tylenol for pain relief, Neutrogena for skincare, Listerine for oral care, Band-Aid for wound care, and Johnson’s Baby for infant products. Others like Aveeno (oat-based skincare), Benadryl (allergy relief), Zyrtec (antihistamines), and Visine (eye care) cater to diverse needs, emphasizing science-backed solutions for everyday wellness.
These brands, many over 100 years old, drive loyalty and market share. For instance, Neutrogena’s Hydro Boost line and Tylenol’s Proactive Joint Care exemplify Kenvue’s focus on proactive health. The portfolio’s strength is a key factor in the Kimberly-Clark deal, promising cross-selling opportunities in high-growth categories like skin health and essential care.
Leadership and Governance at Kenvue
Under Kirk Perry’s leadership as permanent CEO since mid-2025, Kenvue prioritizes innovation and consumer trust. Perry, a seasoned executive, oversees a team including Anindya Dasgupta as Group President for Asia Pacific, leveraging 30 years of expertise. The board, chaired by Larry Merlo, balances independence with industry insight, ensuring alignment with shareholder interests.
Governance highlights include robust ESG commitments and transparency, as detailed in the 2025 Proxy Statement. This framework supports Kenvue’s mission: “A new view of care,” fostering generations of trust through ethical practices.
Financial Performance and Market Position
Kenvue’s financials reflect a mature yet challenged operator. In 2024, it posted $15.5 billion in revenue and $1.03 billion in net income, with total assets of $25.6 billion. Q3 2025 showed net sales down 3.5% year-over-year (organic sales -4.4%), with diluted EPS at $0.21 and adjusted EPS at $0.28. Full-year 2025 guidance anticipates low single-digit declines in sales, impacted by litigation reserves and market softness.
Despite this, Kenvue’s addition to the S&P 500 Dividend Aristocrats in 2023 signals dividend reliability. The acquisition premium—14.3x LTM adjusted EBITDA—validates its undervalued potential.
Looking Ahead: Implications for Ownership and the Industry
The Kimberly-Clark merger could redefine Kenvue’s ownership, blending two titans into a consumer staples giant. If approved, it promises accelerated growth, enhanced R&D, and broader distribution, potentially boosting “Kenvue stock outlook” searches. Yet, regulatory scrutiny—especially on antitrust grounds—looms, with closure slated for late 2026.
For now, Kenvue’s current owners—institutional giants and J&J—benefit from its resilient brands. As the deal unfolds, stakeholders must monitor integration risks, like supply chain overlaps. Ultimately, this evolution reinforces Kenvue’s legacy: From J&J spin-off to potential merger powerhouse, ownership reflects a commitment to consumer-centric innovation.
References
- Kimberly-Clark to Acquire Kenvue, Creating a $32 Billion Global Health and Wellness Leader. https://investors.kenvue.com/financial-news/news-details/2025/Kimberly-Clark-to-Acquire-Kenvue-Creating-a-32-Billion-Global-Health-and-Wellness-Leader/default.aspx
- Kenvue – Wikipedia. https://en.wikipedia.org/wiki/Kenvue
- Kenvue Inc.: Shareholders Board Members Managers and Company Profile. https://www.marketscreener.com/quote/stock/KENVUE-INC-154055852/company/
- Kimberly-Clark bets $40 billion for Kenvue despite Tylenol controversy. https://www.reuters.com/business/healthcare-pharmaceuticals/kimberly-clark-acquire-kenvue-487-billion-deal-2025-11-03/
- Kenvue becomes a fully independent company following final separation from Johnson & Johnson. https://www.kenvue.com/media/kenvue-becomes-a-fully-independent-company
